Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin degludec plus oral semaglutide vs insulin degludec plus dapagliflozin in type 2 diabetes
jRCT1031220271Not yet recruiting
- Start
- Aug 2022
- Modality
- Recombinant Proteins and Enzymes, Peptides, Small Molecules
- Countries
- 1
01
Overview
Randomised trial in type 2 diabetes mellitus (T2DM) comparing Insulin degludec + dapagliflozin with Insulin degludec + oral semaglutide (2 arms). Primary endpoint: Change in HbA1c at 24 weeks. Planned start Aug 2022; status: not yet recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT1031220271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031220271.